Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 2Sarcoma 1Recurrence 1Prostatic Neoplasms 1Leiomyosarcoma 1Glioblastoma 1

Interventions

Doxorubicin 15pembrolizumab 12Cyclophosphamide 9Surgical Procedures, Operative 8Gemcitabine 8Blood Specimen Collection 8Ifosfamide 7Surveys and Questionnaires 6Nivolumab 6Trabectedin 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Drug Therapy 5fludarabine 4Temozolomide 4Specimen Handling 4Radiation Dose Hypofractionation 4Biopsy 4selinexor 3pazopanib 3liposomal doxorubicin 3cabozantinib 3atezolizumab 3anlotinib 3Radiation 3Observation 3Docetaxel 3Dacarbazine 3trastuzumab deruxtecan 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma × ADI PEG20 × Clear all
NCT05712694 2026-04-20

Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

Polaris Group

Phase 3 Recruiting
300 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡